Please assess the completion status of the following clinical trial:

Trial Title: Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes can and will comply with the requirements of the protocol.~* A male or non-pregnant female 18 to 50 years of age at the time of first vaccination.~* Written informed consent obtained from the subject before screening procedures.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~* Available to participate for the duration of the study.~* Female subjects of non-childbearing potential.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate Food and Drug Administration (FDA)-approved contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of vaccination, and~ * has agreed to continue adequate FDA-approved contraception during the entire treatment period and for 2 months after completion of the vaccination series and/or malaria challenge.~* Pass a comprehension assessment test.~Exclusion Criteria:~* Use of any investigational or non-registered product within 30 days preceding the first dose of study vaccine, or planned use of any investigational or non-registered product other than the study vaccines during the study period.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 7 days of the first dose of vaccines.~* Prior receipt of an investigational malaria or adenovirus vaccine.~* Chronic use of antibiotics with antimalarial effects.~* History of malaria chemoprophylaxis within 60 days prior to vaccination.~* Any history of malaria.~* Planned travel to malaria endemic areas during the study period.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s) including latex.~* History of allergic disease or reactions likely to be exacerbated by chloroquine.~* History of psoriasis and porphyria, which may be exacerbated after chloroquine treatment.~* Current use of medications known to cause drug reactions to chloroquine, such as antacids and kaolin.~* Any history of anaphylaxis in reaction to any previous vaccination.~* History of severe reactions to mosquito bites.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~* Chronic administration of immunosuppressants or other immune modifying drugs within six months prior to first vaccine dose.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including immunodeficiency virus (HIV) infection.~* Family history of congenital or hereditary immunodeficiency.~* History of splenectomy.~* Major congenital defects or serious chronic illness.~* History of any neurological disorders or seizures.~* Acute disease and/or fever at the time of enrollment.~* Acute disease is defined as the presence of a moderate or severe illness with or without fever. Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* Any abnormal baseline laboratory screening tests.~* Evidence of increased cardiovascular disease risk, moderate or high, according to the NHANES I criteria.~* An abnormal baseline screening electrocardiogram (EKG).~* Hepatomegaly, right upper quadrant abdominal pain or tenderness.~* Personal history of autoimmune disease.~* Seropositive for hepatitis B surface antigen or Hepatitis C virus (antibodies to HCV).~* Pregnant or lactating female.~* Female who intends to become pregnant during the study or planning to discontinue contraceptive measures.~* Suspected or known current alcohol abuse.~* Chronic or active intravenous drug use.~* History of blood donation within 56 days preceding enrolment.~* Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Ad35.CS.01 Group (Type: EXPERIMENTAL): Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered one dose of Ad35.CS.01 vaccine at Month 0, and 2 doses of GSK257049 at Months 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
- GSK257049 Group (Type: EXPERIMENTAL): Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered 3 doses of GSK257049 vaccine at Months 0, 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
- Control Group (Type: EXPERIMENTAL): Healthy male or non-pregnant female subjects, aged 18 to 50 years, were volunteers who did not receive any immunization but were subjected to the sporozoite challenge. The duration of the study was approximately 8 months for infectivity control subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).